Name | Value |
---|---|
Revenues | 8.2M |
Cost of Revenue | 1.9M |
Gross Profit | 6.2M |
Operating Expense | 20.3M |
Operating I/L | -14.1M |
Other Income/Expense | 2.5M |
Interest Income | 2.5M |
Pretax | -11.6M |
Income Tax Expense | 0.0M |
Net Income/Loss | -11.6M |
MaxCyte, Inc. is a global life sciences company specializing in the development and commercialization of next-generation cell therapies. The company's product portfolio includes ExPERT ATx, ExPERT STx, ExPERT GTx, and ExPERT VLx, which are advanced electroporation instruments for transfection and cell engineering. Additionally, MaxCyte offers disposable processing assemblies (PAs) and related accessories to support cell processing and electroporation. The company generates revenue through the sale of its innovative electroporation instruments, disposable processing assemblies, and associated accessories, catering to the needs of researchers and biopharmaceutical companies involved in cell therapy and drug development.